Jeffery L Kutok

This inventor holds 11 USPTO granted patents and 22 published patent applications, plus 4 CIPO patents and 6 EPO patents. Top assignees: Infinity Pharmaceuticals, Inc., Dana-Farber-Cancer Institute Inc., Fundacion Sales. Active years: 2015-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffery L Kutok. Retrieved from https://idiyas.com/inventor/jeffery-l-kutok

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 22)

% Patents Active = 100.0

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 30(Granted Patents)

Company Filing History:

6 out of 108

Infinity Pharmaceuticals, Inc.

patents

5 out of 1,268

Dana-Farber-Cancer Institute Inc.

Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet)

patents

5. 3 out of 1,428

The Brigham and Women's Hospital, Inc.

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11944631 - Combination therapies (2024-04-02),

2. 11723972 - Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 (2023-08-15),

3. 11541059 - Heterocyclic compounds and uses thereof (2023-01-03),

4. 11147818 - Combination therapies (2021-10-19),

5. 11110096 - Combination therapies (2021-09-07),

6. 10675286 - Heterocyclic compounds and uses thereof (2020-06-09),

7. 10456465 - Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 (2019-10-29),

8. 9939428 - Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1 (2018-04-10),

9. 9775844 - Heterocyclic compounds and uses thereof (2017-10-03),

10. 9206427 - Compositions, kits, and methods for the modulation of immune responses using galectin-1 (2015-12-08),

11. 8968740 - Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 (2015-03-03),

Title: The Innovative Journey of Jeffery L. Kutok in Cancer Research

Introduction

Jeffery L. Kutok, located in Natick, MA, is an influential inventor in the field of cancer research with a notable portfolio of 11 patents. Throughout his career, he has significantly contributed to the understanding and treatment of various cancer-related disorders, showcasing the impact of his innovative pharmaceutical compositions.

Latest Patents

Kutok's latest patents include groundbreaking work on combination therapies. His invention provides pharmaceutical compositions that comprise a phosphatidylinositol 3-kinase inhibitor alongside a Bcl-2 inhibitor. These compositions are designed for the treatment of cancer, improving ways to administer effective therapies. Another significant contribution by Kutok involves the diagnosis, prognosis, monitoring, treatment, and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders, utilizing galectin-1. This invention highlights the role of galectin-1 in viral-associated PTLD, specifically EBV-associated PTLD, demonstrating his commitment to addressing complex medical challenges.

Career Highlights

Throughout his career, Jeffery L. Kutok has worked with esteemed organizations such as Infinity Pharmaceuticals, Inc. and the Dana-Farber Cancer Institute, Inc. His work at these institutions has positioned him as a leader in cancer research and therapeutic development. His innovative mindset and commitment to advancing medical science have earned him recognition in the field.

Collaborations

Kutok has collaborated with prominent figures such as Margaret A. Shipp and Jing Ouyang. These partnerships reflect his dedication to working with other experts in oncology, fostering a collaborative environment that enhances research and innovation.

Conclusion

In conclusion, Jeffery L. Kutok stands out as a remarkable inventor with significant contributions to cancer treatment innovations. His latest patents and collaborations exemplify his dedication to improving healthcare through research and development. As he continues to innovate, Kutok remains a key figure in the pursuit of effective cancer therapies, impacting countless lives along the way.

Profile summary based on public USPTO records.